These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 36305052)
1. Efficient recall of SARS-CoV-2 variant-reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boosters. Rouers A; Wong N; Goh YS; Torres-Ruesta A; Tay MZ; Chang ZW; Fong SW; Neo V; Kam IKJ; Yeo NK; Huang Y; Loh CY; Hor PX; Wong JXE; Tan YJ; ; Macary PA; Qian X; Bei W; Ngoh EZX; Salleh SNM; Wang CI; Poh XY; Rao S; Chia PY; Ong SWX; Lee TH; Lin RJH; Lim C; Teo J; Ren EC; Lye DC; Young BE; Ng LFP; Renia L J Med Virol; 2023 Jan; 95(1):e28258. PubMed ID: 36305052 [TBL] [Abstract][Full Text] [Related]
2. Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial. Poh XY; Tan CW; Lee IR; Chavatte JM; Fong SW; Prince T; Hartley C; Yeoh AYY; Rao S; Chia PY; Ong SWX; Lee TH; Sadarangani SP; Lin RJH; Lim C; Teo J; Lim DRX; Chia W; Hiscox JA; Ng LFP; Ren EC; Lin RTP; Renia L; Lye DC; Wang LF; Young BE Clin Infect Dis; 2022 Dec; 75(12):2088-2096. PubMed ID: 35543372 [TBL] [Abstract][Full Text] [Related]
3. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Pérez-Then E; Lucas C; Monteiro VS; Miric M; Brache V; Cochon L; Vogels CBF; Malik AA; De la Cruz E; Jorge A; De Los Santos M; Leon P; Breban MI; Billig K; Yildirim I; Pearson C; Downing R; Gagnon E; Muyombwe A; Razeq J; Campbell M; Ko AI; Omer SB; Grubaugh ND; Vermund SH; Iwasaki A Nat Med; 2022 Mar; 28(3):481-485. PubMed ID: 35051990 [TBL] [Abstract][Full Text] [Related]
4. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493 [TBL] [Abstract][Full Text] [Related]
5. Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals. Goh YS; Rouers A; Fong SW; Zhuo NZ; Hor PX; Loh CY; Huang Y; Neo VK; Kam IKJ; Wang B; Ngoh EZX; Salleh SNM; Lee RTC; Pada S; Sun LJ; Ong DLS; Somani J; Lee ES; ; ; Maurer-Stroh S; Wang CI; Leo YS; Ren EC; Lye DC; Young BE; Ng LFP; Renia L Front Immunol; 2022; 13():1031852. PubMed ID: 36451833 [TBL] [Abstract][Full Text] [Related]
6. Humoral and T Cell Immune Responses against SARS-CoV-2 after Primary and Homologous or Heterologous Booster Vaccinations and Breakthrough Infection: A Longitudinal Cohort Study in Malaysia. Fu JYL; Pukhari MH; Bador MK; Sam IC; Chan YF Viruses; 2023 Mar; 15(4):. PubMed ID: 37112825 [TBL] [Abstract][Full Text] [Related]
7. BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults. Seidel A; Zanoni M; Groß R; Krnavek D; Erdemci-Evin S; von Maltitz P; Albers DPJ; Conzelmann C; Liu S; Weil T; Mayer B; Hoffmann M; Pöhlmann S; Beil A; Kroschel J; Kirchhoff F; Münch J; Müller JA Front Immunol; 2022; 13():882918. PubMed ID: 35958601 [TBL] [Abstract][Full Text] [Related]
8. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine. Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938 [TBL] [Abstract][Full Text] [Related]
9. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination. Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410 [TBL] [Abstract][Full Text] [Related]
10. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants. Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765 [TBL] [Abstract][Full Text] [Related]
11. T-Cell Mediated Response after Primary and Booster SARS-CoV-2 Messenger RNA Vaccination in Nursing Home Residents. Schiavoni I; Palmieri A; Olivetta E; Leone P; Di Lonardo A; Mazzoli A; Cafariello C; Malara A; Palamara AT; Incalzi RA; Onder G; Stefanelli P; Fedele G; J Am Med Dir Assoc; 2023 Feb; 24(2):140-147.e2. PubMed ID: 36587928 [TBL] [Abstract][Full Text] [Related]
12. Humoral immune response after different SARS-CoV-2 vaccination regimens. Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798 [TBL] [Abstract][Full Text] [Related]
13. Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination. Assawakosri S; Kanokudom S; Suntronwong N; Auphimai C; Nilyanimit P; Vichaiwattana P; Thongmee T; Duangchinda T; Chantima W; Pakchotanon P; Srimuan D; Thatsanatorn T; Klinfueng S; Yorsaeng R; Sudhinaraset N; Wanlapakorn N; Mongkolsapaya J; Honsawek S; Poovorawan Y J Infect Dis; 2022 Oct; 226(8):1372-1381. PubMed ID: 35267040 [TBL] [Abstract][Full Text] [Related]
14. Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study. Fong CH; Zhang X; Chen LL; Poon RW; Chan BP; Zhao Y; Wong CK; Chan KH; Yuen KY; Hung IF; Yuen JKY; To KK EBioMedicine; 2023 Feb; 88():104446. PubMed ID: 36706582 [TBL] [Abstract][Full Text] [Related]
15. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies. Vargas L; Valdivieso N; Tempio F; Simon V; Sauma D; Valenzuela L; Beltrán C; Castillo-Delgado L; Contreras-Benavides X; Acevedo ML; Acevedo J; Gonzalez RI; Valiente-Echeverría F; Soto-Rifo R; Rosemblatt M; Lopez M; Osorio F; Bono MR BMC Med; 2022 Jun; 20(1):216. PubMed ID: 35676738 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]. Poh XY; Lee IR; Lim C; Teo J; Rao S; Chia PY; Ong SWX; Lee TH; Lin RJH; Ng LFP; Ren EC; Lin RTP; Wang LF; Renia L; Lye DC; Young BE Trials; 2022 Jun; 23(1):498. PubMed ID: 35710572 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of heterologous booster with protein-based COVID-19 vaccine (NVX-CoV2373) in healthy adults: A comparative analysis with mRNA vaccines. Sheng WH; Lin PH; Cheng YC; Wu YY; Hsieh MJ; Yang HC; Chang SY; Chang SC J Formos Med Assoc; 2024 Mar; 123(3):340-346. PubMed ID: 37996322 [TBL] [Abstract][Full Text] [Related]
18. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa. Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842 [TBL] [Abstract][Full Text] [Related]
19. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore. Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588 [TBL] [Abstract][Full Text] [Related]
20. Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients. Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E Front Immunol; 2022; 13():907615. PubMed ID: 35812459 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]